BioMarin Pharmaceutical | BMRN - Operating Expenses


BioMarin Pharmaceutical reported $636.56M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Incyte USD 973.64M 4.65B Jun/2026
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Moderna USD 960M 817M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 8.98B 1.73B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026